Cantargia
OverviewSuggest Edit
Cantargia is a biotechnology company that specializes in the development of pharmaceuticals for various types of cancer, autoimmune and inflammatory diseases. It develops CAN04, an antibody against IL1RAP to recognize cancer cells and stimulate the natural immune system to destroy such cells, as well as block the tumor inflammation.
| Type | Public | |
| Founded | 2010 | |
| HQ | Lund, SE | Map |
| Website | cantargia.com |
Latest Updates
| Employees (est.) (Feb 2020) | 8 | (-42%) |
| Cybersecurity rating | A | More |
Key People/Management at Cantargia
Karin Leandersson
Göran Forsberg
Thoas Fioretos
Bengt Jöndell
Claus Asbjørn Andersson
Patricia Delaite
Cantargia Online and Social Media Presence
Cantargia's Trends
Cantargia News and Updates
BioInvent and Cantargia sign manufacturing agreement for monoclonal antibody CAN10
Cantargia Frequently Asked Questions
When was Cantargia founded?
Cantargia was founded in 2010.
Who are Cantargia key executives?
Cantargia's key executives are Karin Leandersson, Göran Forsberg and Thoas Fioretos.
How many employees does Cantargia have?
Cantargia has 8 employees.
Who are Cantargia competitors?
Competitors of Cantargia include MetaStat, NeOnc Technologies and Sonnet BioTherapeutics.
Where is Cantargia headquarters?
Cantargia headquarters is located at Scheelevägen 27, Lund.
Where are Cantargia offices?
Cantargia has an office in Lund.
How many offices does Cantargia have?
Cantargia has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies